Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes

References

• Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther 2010;3:1–13.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002;16:1151–1162.
   PubMed Web of Science ®Google Scholar
• Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447–5454.
   PubMed Web of Science ®Google Scholar
• Abdel-Aleem S, St Louis JD, Hughes GC, . Metabolic changes in the normal and hypoxic neonatal myocardium. Ann NY Acad Sci 1999;874:254–261.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004;5:405–406.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721–732.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, . Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240–2245.
   PubMed Web of Science ®Google Scholar
• de Jonge HJ, Valk PJ, Veeger NJ, . High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010;116:1747–1754.
   PubMed Web of Science ®Google Scholar
• Dorević G, Matusan-Ilijas K, Babarović E, . Hypoxia inducible factor-1 alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009;28:40.
   PubMed Web of Science ®Google Scholar
• Shyu KG, Hsu FL, Wang MJ, . Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. Exp Cell Res 2007;313:1181–1191.
   PubMed Web of Science ®Google Scholar
• Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790–797.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Liu Q, Zhao B, . Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep 2011;26:1457–1464.
   PubMed Web of Science ®Google Scholar
• Brito LG, Schiavon VF, Andrade JM, . Expression of hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clinics (Sao Paulo) 2011;66: 1313–1320.
   PubMed Web of Science ®Google Scholar
• Aebersold DM, Burri P, Beer KT, . Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911–2916.
   PubMed Web of Science ®Google Scholar
• Birner P, Schindl M, Obermair A, . Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661–1668.
   PubMed Web of Science ®Google Scholar
• Liang X, Zheng M, Jiang J, . Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol 2011;47: 92–97.
   PubMed Web of Science ®Google Scholar
• Park S, Ha SY, Cho HY, . Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 2011;72:100–107.
   PubMed Web of Science ®Google Scholar
• Wellmann S, Guschmann M, Griethe W, . Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004;18:926–933.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Shanafelt TD, Cimmino A, . Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009;113:5568–5574.
   PubMed Web of Science ®Google Scholar
• Stewart M, Talks K, Leek R, . Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin’s lymphoma. Histopathology 2002;40:253–260.
   PubMed Web of Science ®Google Scholar
• Deeb G, Vaughan MM, Mclnnis I, . Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 2011;35:579–584.
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011;14:191–201.
   PubMed Web of Science ®Google Scholar
• Monti E, Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol 2011;4:62–77.
   PubMedGoogle Scholar
• Sullivan R, Par GC, Frederiksen LJ, . Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008;7:1961–1973.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Zhong H, De Marzo AM, Laughner E, . Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999;59:5830–5835.
   PubMed Web of Science ®Google Scholar
• Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000;72: 131–133.
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Holm MS, Guldberg P, . Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006;76:23–32.
   PubMed Web of Science ®Google Scholar
• Lin J, Yao DM, Qian J, . Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 2008;32:1541–1545.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao D, Zhao H, . Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis. Med Oncol 2012 Jan 19. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wu SJ, Yao M, Chou WC, . Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006;135: 317–323.
   PubMed Web of Science ®Google Scholar
• Benetatos L, Dasoula A, Syed N, . Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia 2008;22:1293–1295.
   PubMed Web of Science ®Google Scholar